Hybrid Valve Market Hit US$ 1.81 Bn by 2026 | CAGR of 7.2%
/
Date12 Feb 2020
Email Print Friendly Share The Hybrid Valve Market is anticipated to grow at a CAGR of 7.2% during the forecast period 2019 to 2026 and... Read More →
Adverum Biotechnologies Announces Pricing of Public Offering of Common Stock
/
Date12 Feb 2020
Email Print Friendly Share REDWOOD CITY, Calif., Feb. 11, 2020 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical... Read More →
Western Forest Products Inc. Confirms Record Date of First Quarter 2020 Dividend
/
Date12 Feb 2020
Email Print Friendly Share VANCOUVER, British Columbia, Feb. 11, 2020 (GLOBE NEWSWIRE) — Western Forest Products Inc. (TSX: WEF) (“Western” or the “Company”) is pleased... Read More →
Western Announces Fourth Quarter 2019 Results
/
Date12 Feb 2020
Email Print Friendly Share VANCOUVER, British Columbia, Feb. 11, 2020 (GLOBE NEWSWIRE) — Western Forest Products Inc. (TSX: WEF) (“Western” or the “Company”) reported negative... Read More →
Cross Keys Capital Advises on Mid-Atlantic Retina Practice Affiliation
/
Date12 Feb 2020
Email Print Friendly Share Ft. Lauderdale, FL, Feb. 11, 2020 (GLOBE NEWSWIRE) — Cross Keys Capital served as the exclusive M&A advisor to The Retina... Read More →
Acadia Healthcare Announces Date for Fourth Quarter and Year-End 2019 Earnings Release
/
Date12 Feb 2020
Email Print Friendly Share FRANKLIN, Tenn., Feb. 11, 2020 (GLOBE NEWSWIRE) — Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its fourth... Read More →
International Petroleum Corporation 2019 Year-End Financial Results and 2020 Budget, Production and Resource Guidance
/
Date12 Feb 2020
Email Print Friendly Share International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) today released its financial and operating results and related management’s... Read More →
Lilly et Incyte dévoilent des premiers résultats positifs pour l’étude nord-américaine de phase III (BREEZE-AD5) sur le baricitinib, un inhibiteur sélectif des protéines JAK, destiné au traitement oral de la dermite atopique modérée ou sévère
/
Date12 Feb 2020
Email Print Friendly Share Le baricitinib a satisfait au critère d’évaluation principal de l’étude, soit une réduction d’au moins 75 % de l’inflammation cutanée, et aux critères... Read More →
GREENROSE ACQUISITION CORP. ANNOUNCES PRICING OF $150 MILLION INITIAL PUBLIC OFFERING
/
Date12 Feb 2020
Email Print Friendly Share Woodbury, NY, Feb. 11, 2020 (GLOBE NEWSWIRE) — Greenrose Acquisition Corp. (Nasdaq: GNRSU) (the “Company”) announced today that it priced its... Read More →